Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study
Toole, J.W.P.
Skin Therapy Letter 12(4): 1-3
2007
ISSN/ISBN: 1201-5989 PMID: 17551662 Document Number: 614357
Psoriasis is a common skin disease affecting 1%-3% of the world's population with significant impacts on quality of life. There is a great need for therapies that are efficacious and safe, not only for the short-term, but also for long-term management. Dovobet/ Daivobet/ Taclonex is a product combining two molecules, calcipotriol and betamethasone dipropionate, that may offer psoriatic patients with an option for maintenance therapy. The efficacy and safety of this combined formulation when used over a 4-week period is well documented. A recent publication in the British Journal of Dermatology discusses the safety of this product when used for 52 weeks.